How To Boost AAV Titer With Feed Supplementation In Both HEK293 And Sf-9 Platforms

Adeno-associated virus (AAV) is a widely used vector for gene delivery in treating genetic diseases. However, achieving high levels of infectious AAV particles remains a key challenge in product development. To overcome this, optimizing media and processes is critical to increasing AAV titers and expanding treatment availability.

The two predominant AAV production platforms in the viral and gene therapy (VGT) industry are transiently transfected HEK293 cells and baculovirus-infected Sf-9 insect cells. This webinar highlights the significant impact of feeding cell cultures post-transfection (HEK293) or post-infection (Sf-9) on boosting AAV titers. Data demonstrates the effectiveness of Cellvento® ModiFeed Prime COMP in enhancing yields across both platforms.

MilliporeSigma provides a suite of tools tailored to these platforms, including cell lines, media, and feeds, all designed to optimize production efficiency. Participants will gain insights into comparing AAV production in HEK293 and Sf-9 cells, the role of post-transfection and post-infection feeding strategies in maximizing titers, and practical tips for fine-tuning these approaches.

By addressing the need for high AAV titers, these advancements not only facilitate the scalability of AAV production but also help meet the growing demand for gene therapy treatments. This webinar offers actionable strategies and solutions to improve AAV yields, supporting the development of life-saving therapies.